

# Accepted Manuscript

## Shortening the Washout to 4 Weeks when Switching from Natalizumab to Fingolimod and Risk of Disease Reactivation in Multiple Sclerosis

Y. Naegelin , M. Rasenack , M. Andelova , S. Von Felten ,  
B. Fischer-Barnicol , M. Amann , M. Mehling , L. Kappos ,  
T. Sprenger , T. Derfuss

PII: S2211-0348(18)30205-0  
DOI: [10.1016/j.msard.2018.07.005](https://doi.org/10.1016/j.msard.2018.07.005)  
Reference: MSARD 880

To appear in: *Multiple Sclerosis and Related Disorders*

Received date: 17 March 2018  
Revised date: 21 June 2018  
Accepted date: 2 July 2018

Please cite this article as: Y. Naegelin , M. Rasenack , M. Andelova , S. Von Felten , B. Fischer-Barnicol , M. Amann , M. Mehling , L. Kappos , T. Sprenger , T. Derfuss , Shortening the Washout to 4 Weeks when Switching from Natalizumab to Fingolimod and Risk of Disease Reactivation in Multiple Sclerosis, *Multiple Sclerosis and Related Disorders* (2018), doi: [10.1016/j.msard.2018.07.005](https://doi.org/10.1016/j.msard.2018.07.005)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Highlights:**

- When switching from natalizumab to fingolimod a washout period of 4 weeks is safe
- Number of relapses before switching is associated with the hazard of relapse
- A shorter washout reduces the hazard of relapse
- A shorter washout reduces the risk of disease reactivation over two years

ACCEPTED MANUSCRIPT

Download English Version:

<https://daneshyari.com/en/article/8647161>

Download Persian Version:

<https://daneshyari.com/article/8647161>

[Daneshyari.com](https://daneshyari.com)